Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707328 · ClinicalTrials.gov registry record · Phase 1
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
A Phase 1 study, sponsored by The Cooper Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02707328: Clinical Trial Phase 1 study, sponsored by The Cooper Health System.
NCT02707328 is a Phase 1 study that was terminated before completion, run by The Cooper Health System. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02707328, a Phase 1 study, was terminated before completion, sponsored by The Cooper Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
Primary Outcome
This study is to evaluate the MTD for Cyberknife when given in conjunction with Gemcitabine and Abraxane.
Interventions
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- RADIATION CyberKnife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Why NCT02707328 stopped before completion
NCT02707328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02707328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02707328 about?
NCT02707328 is a clinical study titled "Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)". This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
What is the current status of trial NCT02707328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-01. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT02707328?
The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), CyberKnife (RADIATION).
Who is sponsoring clinical trial NCT02707328?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02707328's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia